20,322.00
+3.16%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neuland Laboratories
Its shares trade on NSE under the ticker NEULANDLAB.NS. It has been listed since 18 April 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹20.23bn and net income of ₹3.64bn. At that date it held total assets of ₹29.30bn and shareholders' equity of ₹18.74bn.
Neuland Laboratories Ltd. engages in the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company is headquartered in Hyderabad, Telangana. The firm caters to both domestic and international markets. The company manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The firm provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The firm operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The firm has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Apr 1994
- Employees
- 1,573
- Website
- neulandlabs.com ↗
Leadership
Pay as last reported
- Dr. Davuluri RaoExecutive Chairman of the Board, since 2021₹33.0m
- Mr. Davuluri RaoChief Executive Officer, Whole Time Vice Chairman of the Board, since 2016₹30.0m
- Mr. Davuluri RaoWhole Time Vice Chairman of the Board, Joint Managing Director₹30.0m
- Mr. Abhijit MajumdarChief Financial Officer
- Dr. Sharadsrikar KotturiChief Scientific Officer
- Ms. Sarada BhamidipatiCompliance Officer, Company Secretary
- Mr. Ashutosh SinhaChief Quality Officer
- Ms. Pallavi BhakruAdditional Independent Director
- Dr. Ravi GopinathAdditional Independent Director
- Mr. Prasad MenonAdditional Independent Director
- Mr. Sugata SircarAdditional Independent Director
- Mr. Homi KhusrokhanNon-Executive Independent Director₹1.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neuland Laboratories Ltd. manufactures APIs and intermediates for generics industry with 1,573 employees.
- The company provides end-to-end solutions for pharmaceutical chemistry needs from synthesis to commercial launch.
- Neuland offers Levetiracetam, Mirtazapine, Ciprofloxacin, and other APIs for global markets.
Weaknesses
- Neuland operates through a single segment, manufacture of active pharmaceutical ingredients and allied services.
- The company has no mention of international expansion plans beyond current markets.
- Neuland's business verticals are generic drug substances and custom manufacturing solutions only.
Opportunities
- Neuland can leverage its API manufacturing expertise for expanding into new markets like India and Europe.
- The growing demand for generics in the global pharmaceutical industry presents opportunities for Neuland.
- Custom Manufacturing Services (CMS) can attract more clients seeking advanced intermediates and NCEs.
Threats
- Neuland faces competition from established API manufacturers in India and Europe.
- Regulatory changes in the pharmaceutical industry could impact Neuland's operations.
- The company's reliance on a single segment may limit growth in volatile markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.